Pharma and healthcare deals in Q1 2025 remain stable amid shift to scalable global models
Grant Thornton Bharat reports 71 transactions totalling USD 2.6 billion in Q1 2025, with investor activity focused on mid-market…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Intas Pharmaceuticals
Deal value declined by 86.4 per cent in Dec 2024, compared to Dec 2023
Three major deals contributed 70 per cent of the total deal value during December 2024
Accord BioPharma’s Biosimilar IMULDOSA gains USFDA approval for treatment of chronic inflammatory…
Intas Pharmaceuticals acquired exclusive commercialisation rights to DMB-3115 through a license agreement in 2021
Intas Pharma signs licensing pact with mAbxience for etanercept biosimilar
Intas gains exclusive commercialisation rights for Etanercept biosimilar for more than 150 countries worldwide
Intas Pharma and Comera Life Sciences enter into a research partnership
The companies will collaborate to develop bio-innovative biologic medicines
Intas launches Oral Azacitidine for adult patients with Acute Myeloid Leukaemia
With this, it becomes the first company to do so
UK fines pharma companies $360 million for overcharging NHS
The watchdog said the firms charged the NHS "excessively high prices" for almost a decade for the steroid hydrocortison
NPPA fixes retail prices of 30 formulations, rejects four applications
Two applications each of Micro Laboratories and Sun Pharma have been deferred by the authority
NPPA fixes retail prices for 14 formulations
The fixed formulations are used to treat diabetes, hypertension, cholesterol, women’s health and mental health disorders
RPG Life Sciences to sell off its biotech unit
To concentrate on expansion of its formulation biz which currently contributes over 60 per cent to the company’s overall sales
RPG…